摘要
The patient population suffering from pancreatic ductal adenocarcinoma(PDAC)presents,as a whole,with a high degree of molecular tumor heterogeneity.The heterogeneity of PDAC tumor composition has complicated treatment and stalled success in clinical trials.Current in vitro techniques insufficiently replicate the intricate stromal components of PDAC tumor microenvironments(TMEs)and fail to model a given tumor's unique genetic phenotype.The development of patient-derived organoids(PDOs)has opened the door for improved personalized medicine since PDOs are derived directly from patient tumors,thus preserving the tumors'unique behaviors and genetic phenotypes.This study developed a tumor-chip device engineered to mimic the PDAC TME by incorporating PDOs and stromal cells,specifically pancreatic stellate cells and macrophages.Establishing PDOs in a multicellular microfluidic chip device prolongs cellular function and longevity and successfully establishes a complex organotypic tumor environment that incorporates desmoplastic stroma and immune cells.When primary cancer cells in monoculture were subjected to stroma-depleting agents,there was no effect on cancer cell viability.However,targeting stroma in our tumor-chip model resulted in a significant increase in the chemotherapy effect on cancer cells,thus validating the use of this tumor-chip device for drug testing.
基金
supported by the Brinson Foundation.F.B.was supported by the National Institutes of Health grant AA025387 and grant number SUL1TR002389-02,which funds the Institute for Translational Medicine(ITM).
